Clinical Trial Update: TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (TORCH) comparing Tarceva (erlotinib) with chemotherapy for advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED